[VIRTUAL] Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study

[VIRTUAL] Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC

[VIRTUAL] Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study

[VIRTUAL] KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma

[VIRTUAL] Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients

[VIRTUAL] A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

[VIRTUAL] Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010

[VIRTUAL] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)

[VIRTUAL] Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)

[VIRTUAL] A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer

[VIRTUAL] Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC

[VIRTUAL] The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma

[VIRTUAL] Single-arm multicentre phase II study of bevacizumab (B) combined with 9-weekly alternating CAPOX and CAPIRI as first-line treatment of patients with metastatic colorectal cancer (mCRC): Main results of the AXOAXI-trial

[VIRTUAL] CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

[VIRTUAL] Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study